Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety

Journal of Psychiatric Research

Volumn 58, Issue , 2014, Pages 161-166

  Ballard, Elizabeth D ^a   Ionescu, Dawn F ^a   Vande Voort, Jennifer L ^a   Niciu, Mark J ^a   Richards, Erica M ^a   Luckenbaugh, David A ^a   Brutsché, Nancy E ^a   Ameli, Rezvan ^a   Furey, Maura L ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Depression; Ketamine; Suicidal ideation; Suicide

Indexed keywords

KETAMINE; PLACEBO; ANALGESIC AGENT;

ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR I DISORDER; BIPOLAR II DISORDER; DSM-IV; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POST HOC ANALYSIS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; DEPRESSION; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS; DEPRESSION; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC; SUICIDAL IDEATION; YOUNG ADULT;

EID: 84912075029     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.07.027     Document Type: Article

References (52)

1. Baca-Garcia E., Perez-Rodriguez M.M., Oquendo M.A., Keyes K.M., Hasin D.S., Grant B.F., et al. Estimating risk for suicide attempt: are we asking the right questions? Passive suicidal ideation as a marker for suicidal behavior. JAffect Disord 2011, 134:327-332.
2. Ballard E.D., Ionescu D.F., Voort J.L., Slonena E.E., Franco-Chaves J.A., Zarate C.A., et al. Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. JAffect Disord 2014, 162:34-38.
3. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
4. Beck A.T., Weissman A., Lester D., Trexler L. The measurement of pessimism: the hopelessness scale. JConsult Clin Psychol 1974, 42:861-865.
5. Beck A.T., Kovacs M., Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. JConsult Clin Psychol 1979, 47:343-352.
6. Beck A.T., Steer R.A., Kovacs M., Garrison B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 1985, 142:559-563.
7. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
8. Brown G.K., Steer R.A., Henriques G.R., Beck A.T. The internal struggle between the wish to die and the wish to live: a risk factor for suicide. Am J Psychiatry 2005, 162:1977-1979.
9. Brown G.K., Ten Have T., Henriques G.R., Xie S.X., Hollander J.E., Beck A.T. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA 2005, 294:563-570.
10. Carlson P.J., Diazgranados N., Nugent A.C., Ibrahim L., Luckenbaugh D.A., Brutsche N., et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 2013, 73:1213-1221.
11. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control National Violent Death Reporting System 2013, [Cited July 7, 2014]. Available from URL:. http://www.cdc.gov/ncipc/wisqars.
12. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control Web-based Injury Statistics Query and Reporting System (WISQARS) 2013, [Cited July 7, 2014]. Available from URL:. http://www.cdc.gov/ncipc/wisqars/nvdrs.
13. Cleary P., Guy W. Factor analysis of Hamilton depression scale. Drugs Exp Clin Res 1977, 115-120.
14. Conwell Y., Duberstein P.R., Cox C., Herrmann J.H., Forbes N.T., Caine E.D. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry 1996, 153:1001-1008.
15. Cornwell B.R., Salvadore G., Furey M., Marquardt C.A., Brutsche N.E., Grillon C., et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 2012, 72:555-561.
16. Cuijpers P., de Beurs D.P., van Spijker B.A., Berking M., Andersson G., Kerkhof A.J. The effects of psychotherapy for adult depression on suicidality and hopelessness: a systematic review and meta-analysis. JAffect Disord 2013, 144:183-190.
17. Desseilles M., Perroud N., Guillaume S., Jaussent I., Genty C., Malafosse A., et al. Is it valid to measure suicidal ideation by depression rating scales?. JAffect Disord 2012, 136:398-404.
18. Diazgranados N., Ibrahim L., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. JClin Psychiatry 2010, 71:1605-1611.
19. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. Arandomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
20. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
21. Duncan W.C., Sarasso S., Ferrarelli F., Selter J., Riedner B.A., Hejazi N.S., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013, 16:301-311.
22. Fava M., Rush A.J., Alpert J.E., Carmin C.N., Balasubramani G.K., Wisniewski S.R., et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiat 2006, 51:823-835.
23. Fawcett J., Scheftner W.A., Fogg L., Clark D.C., Young M.A., Hedeker D., et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990, 147:1189-1194.
24. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV TR axis I disorders, research version 2001, New York State Psychiatric Institute, Biometrics Research, New York. Patient Edition.
25. Frogley C., Taylor D., Dickens G., Picchioni M. Asystematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 2012, 15:1351-1371.
26. Gibbons R.D., Brown C.H., Hur K., Davis J., Mann J.J. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69:580-587.
27. Goldberg D., Fawcett J. The importance of anxiety in both major depression and bipolar disorder. Depress Anxiety 2012, 29:471-478.
28. Hamilton M. The assessment of anxiety states by rating. Brit J Med Psychol 1959, 32:50-55.
29. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
30. Hawton K., Casanas I.C.C., Haw C., Saunders K. Risk factors for suicide in individuals with depression: a systematic review. JAffect Disord 2013, 147:17-28.
31. Hennen J., Baldessarini R.J. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005, 73:139-145.
32. Ibrahim L., Diazgranados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacol 2012, 37:1526-1533.
33. Ionescu D.F., Luckenbaugh D.A., Niciu M.J., Richards E.M., Slonena E.E., Vande Voort J.L., et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. JClin Psychiatry 2014, In press.
34. Irwin S.A., Iglewicz A., Nelesen R.A., Lo J.Y., Carr C.H., Romero S.D., et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. JPalliat Med 2013, 16:958-965.
35. Kavalali E.T., Monteggia L.M. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 2012, 3:12040531.
36. Larkin G.L., Beautrais A.L. Apreliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011, 14:1127-1131.
37. Luckenbaugh D.A., Niciu M.J., Ionescu D.F., Nolan N.M., Richards E.M., Brutsche N.E., et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. JAffect Disord 2014, 159:56-61.
38. McClintock S.M., Husain M.M., Bernstein I.H., Wisniewski S.R., Trivedi M.H., Morris D., et al. Assessing anxious features in depressed outpatients. Int J Method Psych 2011, 20:e69-82.
39. Niciu M.J., Luckenbaugh D.A., Ionescu D.F., Guevara S., Machado-Vieira R., Richards E.M., et al. Clinical predictors of ketamine response in treatment-resistant major depression. JClin Psychiatry 2014, 75:e417-e423.
40. Niciu M.J., Matthews D.C., Nugent A.C., Ionescu D.F., Furey M.L., Richards E.M., et al. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety 2014, 31:297-307.
41. Nock M.K., Hwang I., Sampson N.A., Kessler R.C. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry 2010, 15:868-876.
42. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526.
43. Price R.B., Iosifescu D.V., Murrough J.W., Chang L.C., Al Jurdi R.K., Iqbal S.Z., et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014, 31:335-343.
44. Quiroz J.A., Machado-Vieira R., Zarate C.A., Manji H.K. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiol 2010, 62:50-60.
45. Rappaport L.M., Moskowitz D.S., Galynker I., Yaseen Z.S. Panic symptom clusters differentially predict suicide ideation and attempt. Compr Psychiat 2014, 55:762-769.
46. Sareen J., Cox B.J., Afifi T.O., de Graaf R., Asmundson G.J., ten Have M., et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005, 62:1249-1257.
47. Schmitz A., Grillon C. Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc 2012, 7:527-532.
48. Ting S.A., Sullivan A.F., Boudreaux E.D., Miller I., Camargo C.A. Trends in US emergency department visits for attempted suicide and self-inflicted injury, 1993-2008. Gen Hosp Psychiatry 2012, 34:557-565.
49. U.S. Department of Health and Human Services (HHS) 2012 National Strategy for Suicide Prevention: Goals and objectives for action 2012, Office of the Surgeon General and National Action Alliance for Suicide Prevention, HHS, Washington, DC.
50. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. Arandomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
51. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71:939-946.
52. Zigman D., Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. JClin Psychopharmacol 2013, 33:270-272.